Aspira Women’s Health (NASDAQ:AWH) Rating Increased to Hold at StockNews.com

Aspira Women’s Health (NASDAQ:AWH) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report released on Wednesday.

Separately, Cantor Fitzgerald decreased their price objective on Aspira Women’s Health from $4.00 to $3.30 and set a “neutral” rating for the company in a research report on Monday.

Aspira Women’s Health Stock Down 3.6 %

NASDAQ:AWH opened at $2.70 on Wednesday. The stock’s 50 day moving average price is $4.12 and its 200 day moving average price is $4.21. The company has a market capitalization of $33.32 million, a PE ratio of -0.22 and a beta of 1.61. Aspira Women’s Health has a 52-week low of $2.31 and a 52-week high of $6.75.

Hedge Funds Weigh In On Aspira Women’s Health

Several hedge funds have recently bought and sold shares of the stock. B. Riley Wealth Advisors Inc. increased its position in Aspira Women’s Health by 43.1% during the fourth quarter. B. Riley Wealth Advisors Inc. now owns 179,371 shares of the company’s stock worth $732,000 after buying an additional 53,997 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Aspira Women’s Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 196,007 shares of the company’s stock valued at $800,000 after purchasing an additional 13,162 shares during the period. Northern Trust Corp grew its position in shares of Aspira Women’s Health by 227.7% in the fourth quarter. Northern Trust Corp now owns 36,049 shares of the company’s stock valued at $147,000 after purchasing an additional 25,047 shares during the period. Quantum Private Wealth LLC grew its position in shares of Aspira Women’s Health by 76.8% in the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after purchasing an additional 21,788 shares during the period. Finally, Northeast Financial Consultants Inc purchased a new stake in shares of Aspira Women’s Health in the third quarter valued at $126,000. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.